PUBLIC COMPANY
save89bio Inc
founded 2018 · 93 employees · San Francisco, CA, USupdated 1mo ago
89bio is a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases. Its lead candidate, pegozafermin, is a glycoPEGylated FGF21 analog in Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia. The company was acquired by Roche in October 2025.
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
comments(0)
5-min edit window · permanent after that